MetaCurUm AB has received a SEK 1 million grant from the Swedish Innovation Agency Vinnova to advance its therapeutic antibody for prostate cancer toward clinical trials. The Vinnova funds will be used further to validate MetaCurUm's mechanism of action and product. MetaCurUm is collaborating with the Institute of Cancer Research in London and Professor Johan de Bono.
MetaCurUm Biotech AB plans to raise 100 million SEK following founder Maréne Landström being named Sweden's Cancer Researcher of the Year. Their groundbreaking cancer treatment, still in the preclinical phase, aims to halt the TGFβ pathway cancer cells utilize. The Umeå based company is collaborating with international researchers and exploring biomarkers for patient stratification.
Umeå Biotech Incubator (UBI) is one of Sweden’s state-of-the-art business incubators within the life sciences. We help researchers to use their data to the benefit of patients and citizens, improving their health. We support and train entrepreneurs in the fields of pharmaceuticals, diagnostics and medical engineering, and act as a bridge between academia, medicine and the business community.
Tvistevägen 48C
907 36 Umeå
Sweden